Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy

Next Previous
Trial Profile

EMBER-3: A Phase 3, Randomized, Open-Label Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Patients With Estrogen Receptor Positive, HER2 Negative Locally Advanced or Metastatic Breast Cancer Previously Treated With Endocrine Therapy

Status: Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 23 Jul 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Imlunestrant (Primary) ; Abemaciclib; Exemestane; Fulvestrant
  • Indications Advanced breast cancer; HER2 negative breast cancer; Male breast cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms EMBER-3
  • Sponsors Eli Lilly and Company

Most Recent Events

  • 22 May 2025 According to an Eli Lilly and Company media release, extended safety analysis from this trial will be presented at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting.
  • 11 Dec 2024 According to an Eli Lilly and Company media release, Komal Jhaveri, M.D is one of the study's principal investigators.
  • 11 Dec 2024 According to an Eli Lilly and Company media release, data from this study is being submitted to regulatory health authorities globally.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top